The insulin-like growth factors (IGF) system, and particularly the IGF-1 receptor, has recently become the subject of major interest in the arena of cancer research. Its involvement in cancer cell growth and survival makes the system an excellent target as potential adjunct therapy to standard chemotherapy.
